Autus Asset Management’s Edwards Lifesciences EW Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q4 | $4.71M | Sell |
63,065
-1,106
| -2% | -$85.2K | 0.85% | 49 |
|
|
2022
Q3 | $5.3M | Sell |
64,171
-133
| -0.2% | -$12.8K | 1.02% | 42 |
|
|
2022
Q2 | $6.11M | Sell |
64,304
-1,344
| -2% | -$139K | 1.09% | 39 |
|
|
2022
Q1 | $7.73M | Sell |
65,648
-33,706
| -34% | -$3.78M | 1.16% | 34 |
|
|
2021
Q4 | $12.9M | Sell |
99,354
-1,915
| -2% | -$223K | 1.29% | 27 |
|
|
2021
Q3 | $11.5M | Sell |
101,269
-2,644
| -3% | -$302K | 1.25% | 29 |
|
|
2021
Q2 | $10.8M | Sell |
103,913
-3,497
| -3% | -$330K | 1.18% | 32 |
|
|
2021
Q1 | $8.98M | Buy |
107,410
+7,341
| +7% | +$621K | 1.06% | 38 |
|
|
2020
Q4 | $9.13M | Sell |
100,069
-13,949
| -12% | -$1.16M | 1.18% | 33 |
|
|
2020
Q3 | $9.1M | Sell |
114,018
-471
| -0.4% | -$36.8K | 1.21% | 30 |
|
|
2020
Q2 | $7.91M | Sell |
114,489
-105
| -0.1% | -$7.46K | 1.15% | 34 |
|
|
2020
Q1 | $7.21M | Sell |
114,594
-3,939
| -3% | -$284K | 1.27% | 32 |
|
|
2019
Q4 | $9.22M | Sell |
118,533
-633
| -0.5% | -$49.4K | 1.34% | 30 |
|
|
2019
Q3 | $8.73M | Sell |
119,166
-6,789
| -5% | -$477K | 1.37% | 29 |
|
|
2019
Q2 | $7.76M | Sell |
125,955
-138
| -0.1% | -$8.35K | 1.23% | 32 |
|
|
2019
Q1 | $8.04M | Sell |
126,093
-4,206
| -3% | -$240K | 1.33% | 29 |
|
|
2018
Q4 | $6.65M | Sell |
130,299
-2,253
| -2% | -$114K | 1.28% | 29 |
|
|
2018
Q3 | $7.69M | Sell |
132,552
-2,772
| -2% | -$136K | 1.28% | 27 |
|
|
2018
Q2 | $6.57M | Sell |
135,324
-3,579
| -3% | -$167K | 1.15% | 34 |
|
|
2018
Q1 | $6.46M | Sell |
138,903
-6,108
| -4% | -$265K | 1.17% | 35 |
|
|
2017
Q4 | $5.45M | Sell |
145,011
-1,260
| -0.9% | -$46.2K | 0.99% | 42 |
|
|
2017
Q3 | $5.33M | Buy |
146,271
+324
| +0.2% | +$12.4K | 1.02% | 42 |
|
|
2017
Q2 | $5.75M | Sell |
145,947
-1,320
| -0.9% | -$48.2K | 1.16% | 38 |
|
|
2017
Q1 | $4.62M | Sell |
147,267
-2,598
| -2% | -$81.3K | 0.97% | 42 |
|
|
2016
Q4 | $4.68M | Buy |
149,865
+3,963
| +3% | +$128K | 1.03% | 40 |
|
|
2016
Q3 | $5.86M | Sell |
145,902
-2,847
| -2% | -$107K | 1.31% | 31 |
|
|
2016
Q2 | $4.94M | Sell |
148,749
-6,690
| -4% | -$229K | 1.13% | 38 |
|
|
2016
Q1 | $4.57M | Sell |
155,439
-17,115
| -10% | -$472K | 1.11% | 37 |
|
|
2015
Q4 | $4.54M | Sell |
172,554
-6,138
| -3% | -$159K | 1.15% | 33 |
|
|
2015
Q3 | $4.23M | Buy |
178,692
+792
| +0.4% | +$19.1K | 1.29% | 29 |
|
|
2015
Q2 | $4.22M | Sell |
177,900
-3,852
| -2% | -$86.9K | 1.18% | 36 |
|
|
2015
Q1 | $4.32M | Sell |
181,752
-21,150
| -10% | -$474K | 1.2% | 37 |
|
|
2014
Q4 | $4.31M | Sell |
202,902
-1,536
| -0.8% | -$30.9K | 1.36% | 35 |
|
|
2014
Q3 | $3.48M | Buy |
204,438
+180
| +0.1% | +$2.84K | 1.17% | 38 |
|
|
2014
Q2 | $2.92M | Buy |
204,258
+1,230
| +0.6% | +$16.7K | 1.01% | 39 |
|
|
2014
Q1 | $2.51M | Buy |
203,028
+27,942
| +16% | +$322K | 0.95% | 37 |
|
|
2013
Q4 | $1.92M | Buy |
175,086
+20,130
| +13% | +$227K | 0.75% | 43 |
|
|
2013
Q3 | $1.8M | Buy |
154,956
+46,050
| +42% | +$539K | 0.76% | 42 |
|
|
2013
Q2 | $1.22M | Buy |
+108,906
| New | +$1.29M | 0.55% | 48 |
|
Other funds holding EW
Autus Asset Management's EW Position: Q4 2022 in Review
Autus Asset Management reduced its Edwards Lifesciences (EW) stake by 1.7% in Q4 2022, selling an estimated $85.2K and leaving 63,065 shares worth $4.71M. The position accounts for 0.85% of the portfolio, ranked #49.
Autus Asset Management first reported a position in EW in Q2 2013 and has held it in 39 quarters since. The position peaked at $12.9M in Q4 2021. 1,228 funds tracked by Wall St. Rank hold EW as of Q4 2022.
- Autus Asset Management held 63,065 shares of Edwards Lifesciences worth $4.71M as of Q4 2022.
- Autus Asset Management sold 1,106 Edwards Lifesciences shares in Q4 2022, an estimated $85.2K.
- Edwards Lifesciences made up 0.85% of Autus Asset Management's portfolio in Q4 2022, its #49 holding.
- Autus Asset Management first reported a position in Edwards Lifesciences in Q2 2013 and has held it in 39 quarters since.
- Autus Asset Management's Edwards Lifesciences position peaked at $12.9M in Q4 2021.
- 1,228 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q4 2022.
Based on Autus Asset Management's 13F filing for Q4 2022, filed 24 Jan 2023.